Bridging pre-surgical endocrine therapy for breast cancer during the COVID-19 pandemic: outcomes from the B-MaP-C study
Pandemic
DOI:
10.1007/s10549-023-06893-4
Publication Date:
2023-04-03T10:23:20Z
AUTHORS (492)
ABSTRACT
Abstract Purpose The B-MaP-C study investigated changes to breast cancer care that were necessitated by the COVID-19 pandemic. Here we present a follow-up analysis of those patients commenced on bridging endocrine therapy (BrET), whilst they awaiting surgery due reprioritisation resources. Methods This multicentre, multinational cohort recruited 6045 from UK, Spain and Portugal during peak pandemic period (Feb–July 2020). Patients BrET followed up investigate duration of, response to, BrET. included in tumour size reflect downstaging potential, cellular proliferation (Ki67), as marker prognosis. Results 1094 prescribed BrET, over median 53 days (IQR 32–81 days). majority (95.6%) had strong ER expression (Allred score 7–8/8). Very few required expedited surgery, lack (1.2%) or tolerance/compliance (0.8%). There small reductions after 3 months’ treatment duration; 4 mm [IQR − 20, 4]. In subset ( n = 47), drop (Ki67) occurred 26 (55%), high (Ki67 ≥ 10%) low (< 10%), with at least one month’s Discussion describes real-world usage pre-operative was found be tolerable safe. data support short-term (≤ months) therapy. Longer-term use should future trials.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (30)
CITATIONS (4)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....